Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir

Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention,...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, Kevin, Maruff, Paul, Ross, Lisa L., Wohl, David, Small, Catherine B, Edelstein, Howard, Shaefer, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416234/
https://www.ncbi.nlm.nih.gov/pubmed/30298202
http://dx.doi.org/10.1007/s13365-018-0680-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416234/
https://www.ncbi.nlm.nih.gov/pubmed/30298202
http://dx.doi.org/10.1007/s13365-018-0680-y

Ejemplares similares